Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Hydroxychloroquine has become established in the management of various forms of cutaneous lupus, photosensitive dermatoses, porphyria cutanea tarda, cutaneous sarcoid, lichen planus and other inflammatory dermatological diseases.1 Dermatologists who prescribe hydroxychloroquine should be aware of new recommendations for retinal screening in all patients on long-term hydroxychloroquine and chloroquine in the United Kingdom.2 The recommendations have been published by the Royal College of Ophthalmologists following a systematic review of the current evidence with input from representatives from the British Society for Rheumatology (BSR)3 and the British Association of Dermatologists (BAD) (Dr. M Ardern-Jones). The recommendations do not apply to mepacrine or quinacrine. This article is protected by copyright. All rights reserved.

Original publication




Journal article


Br j dermatol

Publication Date